Hexal AG
Hexal AG, a prominent player in the pharmaceutical industry, is headquartered in Holzkirchen, Germany. Founded in 1986, the company has established itself as a leader in the development and production of generic medicines, catering to a diverse range of therapeutic areas. With a strong presence across Europe, Hexal AG is renowned for its commitment to quality and innovation, offering a comprehensive portfolio of high-quality generics that are both affordable and effective. The company’s core products include a wide array of prescription medications, which are distinguished by their rigorous quality standards and adherence to regulatory requirements. Hexal AG has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position as a trusted provider in the pharmaceutical sector. With a focus on patient-centric solutions, Hexal AG continues to contribute to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does Hexal AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hexal AG's score of 62 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hexal AG's reported carbon emissions
Hexal AG, headquartered in Germany, currently does not have publicly available data on its carbon emissions, as no specific emissions figures have been provided. Additionally, there are no documented reduction targets or climate pledges outlined in their initiatives. This lack of data suggests that Hexal AG may still be in the early stages of formalising its climate commitments or reporting on its emissions. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Hexal AG to establish clear carbon reduction strategies and transparent reporting practices to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hexal AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
